Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance

Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance

Blog Article

Antimicrobial resistance (AMR) is a global public health threat causing substantial morbidity and mortality as well as significant economic costs.Vaccines can contribute to combating antimicrobial resistance by reducing the incidence m02n3ll/a of resistant disease cases and lowering overall antibiotic use.Greater utilization and investments in vaccines as a tool for combating AMR might be hampered by limited economic evidence demonstrating the AMR-related value of vaccines.

We reviewed the existing literature to assess the state of evidence.We found two modeling studies that provided estimates of AMR-related costs averted by skin of the flayed one pneumococcal vaccination and a few cost-effectiveness studies that exclusively focused on serotype replacement effects on overall vaccine cost-effectiveness.We did not find any cost-effectiveness studies that directly examined the cost-effectiveness of vaccines in slowing the development of AMR.

Further evidence on the cost-effectiveness and economic value of vaccines in controlling AMR can help inform resource allocation decisions and guide development priorities.